Back to News
Market Impact: 0.2

London treaty reinsurance premiums fall 6% in 2025

Source: Investing.com

Company FundamentalsInsurance
London treaty reinsurance premiums fall 6% in 2025

London company-market treaty reinsurance premiums fell 6% in 2025 to £11.27 billion ($15.25 billion), from £11.985 billion in 2024, as underwriting discipline persisted amid competitive pricing. Treaty business remained 26% of London premiums, while the market total was still more than double its £5.32 billion level in 2020. The decline signals near-term pricing and volume pressure, though selective growth and the longer-term expansion of treaty activity provide some support.

Analysis

The relevant signal is not premium volume itself but the persistence of underwriting selectivity despite softer pricing: London-market carriers appear to be sacrificing top-line growth rather than writing marginal treaty risk at inadequate expected returns. That supports near-term reserve quality and capital preservation for disciplined specialty underwriters such as Beazley (BEZ), Hiscox (HSX) and Lancashire (LRE), but limits the case for revenue-driven multiple expansion over the next 1-3 quarters. The more exposed risk is for reinsurers that need premium growth to absorb elevated fixed costs or justify aggressive capital deployment; competitive renewals can compress accident-year margins before it is visible in reported combined ratios.

The key catalyst is the January 2027 renewal season, when cedents’ retained losses, alternative-capital availability and catastrophe experience will determine whether price softening broadens beyond selected lines. A benign North Atlantic hurricane season and continued inflows into insurance-linked securities would favor buyers of reinsurance and pressure listed capacity providers including RenaissanceRe (RNR), Arch Capital (ACGL), Everest Group (EG) and Swiss Re (SREN). Conversely, a material insured-loss event or reserve deterioration in casualty portfolios would rapidly restore pricing power; the market’s leaner treaty growth makes this upside asymmetry more meaningful over 6-18 months.

Consensus may overstate the read-through from lower written premium to weaker earnings. For specialty carriers, declining volume can be economically positive if it reflects exiting low-margin layers, while investment income and favorable prior-year development can mask underwriting deterioration temporarily. The actionable distinction is whether upcoming disclosures show falling rate-on-line and lower attachment points alongside growth; that combination, rather than premium contraction alone, would signal genuine margin erosion.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly negative

Sentiment Score

-0.20

Key Decisions for Investors

  • No broad insurance-sector directional trade on this datapoint alone; use 3Q/4Q underwriting disclosures as the confirmation window. Monitor BEZ, HSX and LRE for rate adequacy, exposure growth and accident-year loss-ratio guidance rather than gross written premium.
  • Maintain a relative-quality bias: long BEZ or LRE versus short a broad reinsurance proxy such as RNR only if January renewal commentary indicates continued rate declines with expanding limits. Target a 6-12 month horizon; invalidate if major-cat losses tighten capacity or BEZ/LRE lower underwriting-margin guidance.
  • For investors already long RNR, ACGL or EG, consider trimming into strength ahead of January renewals if alternative-capital fundraising remains robust and managements report lower property-cat rates. The downside case is 5-10% multiple compression from a reduced ROE outlook; a large insured-loss event is the principal stop-risk.
  • Set alerts for insured catastrophe losses above roughly $50 billion, casualty reserve-strengthening announcements, or meaningful ILS fund outflows. Any of these would reverse the soft-market thesis quickly and favor adding capacity providers rather than shorting them.

More News

From AllMind Research

Browse all research